Ulcerative Proctitis (Investigational Adjunct)
Highly investigational adjunct for distal ulcerative proctitis; case reports only; topical 5-ASA and corticosteroids remain primary.
Patienten-Zusammenfassung
- Ist dies FDA-zugelassen fuer diese Anwendung?
- Not FDA-cleared for ulcerative proctitis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- Welche Evidenz existiert?
- Tier C (investigational). No controlled trials. Evidence-based first-line management of ulcerative proctitis is topical mesalamine (suppositories or enemas) for induction and maintenance, topical corticosteroids for refractory cases, oral mesalamine added if topical therapy is incomplete, and for treatment-refractory disease oral or topical immunomodulators and biologic therapy.
- Hauptrisiken
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Local bleeding into already inflamed and friable rectal tissue
- Risk of seeding infection in an ulcerated mucosa (leeches must NOT be placed on rectal mucosa)
- Wer dies nicht in Betracht ziehen sollte
- Patients with active severe flare with fever, tachycardia, or systemic symptoms (need urgent IBD care)
- Patients who have not had a proper trial of topical mesalamine for at least 4-6 weeks
- Patients with C. difficile or other infectious colitis (treat the infection first)
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
- People with hemophilia or any other inherited bleeding disorder
- Patients with severe anemia (hemoglobin under 10 g/dL)
- People with an active infection at the planned application site
- Was Sie Ihren Kliniker fragen sollten
- Has my proctitis been confirmed by colonoscopy and biopsy as ulcerative (not Crohn or infectious)?
- Have I tried topical mesalamine, topical steroids, and oral mesalamine?
- Have biologic options been discussed if standard therapy has failed?
- What is the published evidence base for leeches in IBD?
- What is the bleeding-risk plan given inflamed mucosa?
- How will worsening of inflammation be detected and managed?
- Wann dringende medizinische Versorgung suchen
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Heavy rectal bleeding, especially with weakness or lightheadedness
- High fever, severe abdominal pain, or signs of bowel perforation
- Inability to pass stool with progressive abdominal distention (possible toxic megacolon)
Was dies NICHT bedeutet
- It does not mean leech therapy is FDA-cleared for ulcerative proctitis — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace topical mesalamine, topical steroids, or biologic therapy.
- It does not change the underlying inflammatory bowel disease.
- It does not lower the long-term colorectal cancer risk that comes with chronic IBD.
- It does not have controlled-trial evidence in IBD.
Sicherheits-Querverweise
Clinical Profile
- Category
- gastrointestinal
- ICD-10
- K51.20, K51.211, K51.219
- Safety tier
- high
Evidence Summary
Ulcerative proctitis (ulcerative colitis limited to the rectum) is managed per ACG and AGA guidelines with topical 5-aminosalicylates (mesalamine suppositories or enemas) as first-line therapy, topical corticosteroids for refractory cases, and oral 5-ASA or biologics for extension or escalation. No controlled clinical trial of leech therapy for ulcerative proctitis has been published; its use is investigational and mechanistic only, and the autoimmune pathophysiology of ulcerative colitis is not directly addressed by leech salivary pharmacology. Direct mucosal (intrarectal or perianal) application is contraindicated. Evidence is grade D.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Wollina U (2009)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Severe acute flare with systemic toxicity
- Toxic megacolon
- Cytomegalovirus or C. difficile superinfection
- Active perianal disease (consider Crohn's)
- Any perianal or intrarectal placement
Related Conditions
Hemorrhoids (Grade II-III, Symptomatic)
Investigational use for symptomatic relief of grade II-III internal/external hemorrhoidal disease; does not address anatomic prolapse.
External Thrombosed Hemorrhoid (Acute, <72h)
Investigational adjunct for acute external thrombosed hemorrhoids presenting within 72 hours; distinct from internal hemorrhoidal disease.
Chronic Anal Fissure (>8 Weeks)
Investigational adjunct for chronic anal fissure refractory to medical therapy; very limited case-report evidence; surgical sphincterotomy remains gold standard.
Non-Alcoholic Fatty Liver Disease (Investigational Adjunct)
Investigational adjunct in NAFLD/MASLD; small case series only; weight loss, dietary modification, and resmetirom remain primary.